Lessons from London and Berlin: Designing A Scalable Gene Therapy Approach for HIV Cure

Christopher W Peterson; Hans-Peter Kiem

doi:10.1016/j.stem.2019.04.010

Lessons from London and Berlin: Designing A Scalable Gene Therapy Approach for HIV Cure

Cell Stem Cell. 2019 May 2;24(5):685-687. doi: 10.1016/j.stem.2019.04.010.

Authors

Christopher W Peterson¹, Hans-Peter Kiem²

Affiliations

¹ Stem Cell and Gene Therapy Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA; Department of Medicine, University of Washington, Seattle, WA 98195, USA.
² Stem Cell and Gene Therapy Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA; Department of Medicine, University of Washington, Seattle, WA 98195, USA; Department of Pathology, University of Washington, Seattle, WA 98195, USA; Washington National Primate Research Center, Seattle, WA 98195, USA. Electronic address: hkiem@fhcrc.org.

PMID: 31051132
DOI: 10.1016/j.stem.2019.04.010

Abstract

Recently in Nature, Gupta et al. (2019) reported that a second patient has achieved HIV-1 remission/functional cure after allogeneic hematopoietic stem cell transplantation from a donor carrying a mutation in the CCR5 coreceptor. We highlight both patients' treatments and summarize efforts to develop a broader, more patient-friendly approach.

Publication types

Research Support, N.I.H., Extramural
Comment

MeSH terms

Berlin
Genetic Therapy
HIV Infections*
HIV-1*
Hematopoietic Stem Cell Transplantation*
Humans
London
Receptors, CCR5

Substances

Receptors, CCR5

Grants and funding

UM1 AI126623/AI/NIAID NIH HHS/United States